prodchem
Aug 20, 2026
The emergence of Khartis Therapeutics with $95 million in total disclosed funding provides a useful benchmark for tracking capital flowing into oral small-molecule immunology companies in 2026.
Khartis announced a $50 million Series B in August 2026, bringing its cumulative financing to $95 million. The company is developing oral small-molecule medicines for immune-mediated and chronic diseases, led by an oral selective IGF-1R inhibitor for thyroid eye disease.
InduPro's $77 million Series B adds another substantial data point. However, it is important to qualify the comparison: InduPro is a broader proximity-biology company whose pipeline spans oncology and immunology, rather than a pure-play oral small-molecule immunology biotech.
Taken together, the two companies represent $172 million of disclosed 2026 financing capital, making them a useful starting benchmark for examining investor appetite for next-generation therapeutic platforms with immunology exposure.
The headline calculation is straightforward:
Company | 2026 Disclosed Financing | Strategic Focus |
|---|---|---|
Khartis Therapeutics | $95M cumulative funding | Oral small-molecule immunology |
InduPro | $77M Series B | Proximity therapeutics; oncology & immunology |
Combined benchmark | $172M | Immunology-related emerging platforms |
Khartis' $95 million represents total capital raised, not necessarily $95 million raised during 2026. Its latest financing was a $50 million Series B.
InduPro's $77 million is specifically a 2026 Series B financing.
That distinction matters when building a true 2026 capital-flow dataset.
Khartis is the stronger fit for the specific theme of oral small-molecule immunology.
The company describes itself as developing first- and best-in-class oral small-molecule medicines for immunological and chronic diseases. Its lead program is an oral selective IGF-1R inhibitor for thyroid eye disease.
Its financing profile includes:
$50M Series B in August 2026
$95M total capital raised
Forge Life Science Partners as Series B lead
Participation from Longwood Fund and Alexandria Venture Investments
Existing backing from Foresite Capital, Lilly Asia Ventures and Nextech Invest
For investors tracking oral immunology, Khartis is therefore a particularly clean benchmark.
InduPro's $77 million Series B is also significant, but its strategic profile is different.
The company is building a proximity-biology platform that uses surface-protein neighborhoods to identify new therapeutic targets and combinations.
Its pipeline includes:
Oncology programs
Immuno-oncology programs
Autoimmune programs
The company specifically describes IDP-003 as a bispecific PD1 agonist for autoimmune disease, while other programs focus on oncology.
That means InduPro should be included in a broad immunology-related capital tracker, but separated from pure oral-small-molecule companies.
The $172 million number is useful, but it should not be described as $172 million of pure 2026 oral-small-molecule immunology financing.
There are three reasons.
The company raised $50 million in its latest Series B, bringing total financing to $95 million.
Its platform spans oncology, immuno-oncology and autoimmune programs.
Its lead clinical program is a proximity-based bispecific antibody-drug conjugate, while its immunology programs are also biologic modalities.
Therefore, $172 million is best treated as a starting benchmark for immunology-related emerging biotech platforms, not a definitive 2026 total for oral small-molecule immunology.
Featured Product
Oral therapies can offer several potential advantages over injectable biologics.
These may include:
Patient convenience
Easier administration
Potentially broader treatment access
Simplified chronic dosing
Reduced dependence on infusion infrastructure
For chronic immune-mediated diseases, convenience can become an important component of a drug's commercial proposition.
However, oral delivery does not automatically produce better clinical outcomes.
Developers still need to demonstrate:
Efficacy
Safety
Selectivity
Pharmacokinetics
Durability
Commercial differentiation
Immunology has become an increasingly attractive area for biotech investors because many disease pathways are already clinically validated.
This can reduce some of the biological uncertainty associated with entirely novel disease mechanisms.
Investors may particularly value programs that combine:
Validated biology + differentiated modality + convenient administration
Khartis' strategy fits this model by combining an established immunology pathway with an oral small-molecule approach.
Khartis' lead program targets thyroid eye disease (TED).
The company is developing an oral selective IGF-1R inhibitor specifically for the condition.
That is strategically interesting because TED is a defined specialty indication where an oral therapy could potentially differentiate itself through administration convenience.
For investors, the important question will be whether an oral approach can provide a sufficiently attractive balance of:
Efficacy
Safety
Convenience
Dosing
Patient persistence
Commercial cost
The $50 million Khartis Series B and $77 million InduPro Series B demonstrate that investors remain willing to provide substantial private capital to biotechnology platforms entering or approaching clinical development.
InduPro's financing was announced alongside the dosing of the first patient in its Phase 1 study.
That suggests investors are willing to finance companies around important development inflection points rather than waiting exclusively for later-stage clinical validation.
InduPro's financing is particularly notable because its investor syndicate includes Merck's MRL Ventures Fund, Sanofi and Eli Lilly, alongside specialist investors.
That creates an important distinction between ordinary venture financing and strategic pharmaceutical participation.
Corporate venture investment can indicate that major drugmakers want exposure to:
New therapeutic platforms
Emerging target biology
Potential licensing opportunities
Future acquisition candidates
Competitive scientific intelligence
InduPro also has a separate licensing relationship with Lonza for ADC technologies supporting its oncology programs.
The real intelligence opportunity is to build a larger 2026 dataset.
Companies should be categorized according to:
Autoimmune
Inflammatory disease
Immunology
Oncology
Rare disease
Oral small molecule
Injectable small molecule
Antibody
Bispecific
ADC
Cell therapy
Gene therapy
Discovery
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Seed
Series A
Series B
Series C+
Strategic financing
This approach would prevent fundamentally different biotech businesses from being treated as equivalent.
A useful 2026 tracker could therefore separate three categories:
Category | Benchmark Example | 2026 Signal |
Pure oral small-molecule immunology | Khartis | $50M latest round / $95M cumulative |
Immunology + broader platform | InduPro | $77M Series B |
Combined disclosed benchmark | Khartis + InduPro | $172M |
The $172 million figure should be presented as a starting benchmark rather than a complete market total.
The eventual intelligence value will come from adding every qualifying 2026 financing and removing double-counting of cumulative capital.
The most important indicators are likely to be:
These provide the clearest evidence of sustained investor appetite.
Clinical entry can materially change valuation expectations.
Strategic investors can provide an important signal of platform attractiveness.
Large partnerships can demonstrate that capital markets interest is translating into pharmaceutical demand.
Ultimately, clinical efficacy and safety will determine whether today's financing enthusiasm is justified.
For large pharmaceutical companies, the financing activity highlights a potentially attractive strategy:
Invest early → establish relationships → monitor clinical validation → retain strategic optionality
This can be more capital-efficient than acquiring a company outright before its therapeutic platform has been validated.
The presence of multiple Big Pharma investors in InduPro's Series B illustrates how this strategy can operate through syndicates.
For private investors, Khartis and InduPro illustrate two different ways to capture immunology-related value.
Khartis:
A focused therapeutic strategy built around oral small molecules and a clinically validated immunology pathway.
InduPro:
A broader platform strategy using proximity biology across oncology and immunology.
The comparison highlights an important investment distinction:
focused asset risk versus platform optionality.
The $172 million figure should not be extrapolated into a market-wide 2026 capital total.
A rigorous market calculation would need to account for:
Undisclosed financing rounds
Cumulative versus current-year funding
Companies with mixed therapeutic pipelines
Companies whose lead assets are not oral
Private strategic investments without disclosed amounts
Venture debt
Licensing payments
Acquisitions
For this reason, the current figure is best described as a disclosed-company benchmark.
Khartis' $95 million cumulative funding and InduPro's $77 million Series B create a useful $172 million starting benchmark for tracking capital flowing toward emerging biotech platforms with meaningful immunology exposure in 2026.
But the data becomes more interesting when the companies are separated by modality.
Khartis is the clearer pure-play example: an oral small-molecule company focused on immunological and chronic diseases. InduPro is broader, combining oncology and immunology with proximity-based biologic approaches.
The next step for market intelligence teams is therefore to expand the dataset and determine how much of 2026's biotech capital is actually flowing into oral small-molecule immunology, rather than simply immunology-related biotechnology.
That distinction could reveal whether investors are specifically returning to oral drug platforms—or whether the apparent capital surge is primarily being driven by broader enthusiasm for validated immunology biology and differentiated therapeutic platforms.
Khartis has raised $95 million cumulatively, including a $50 million Series B announced in August 2026.
InduPro raised $77 million in Series B financing in August 2026.
Together, the companies provide a $172 million disclosed benchmark for immunology-related emerging biotech platforms.
Khartis is the stronger pure-play example for oral small-molecule immunology.
InduPro has a broader oncology and immunology platform and should not be classified as a pure oral-small-molecule company.
The $172 million figure should not be presented as the total 2026 market capital flow because Khartis' figure is cumulative.
Big Pharma participation in InduPro's round adds a strategic-investment dimension to the capital-flow signal.
A larger 2026 financing database should separate therapeutic area, modality, development stage, and financing type.
Found this useful?
Continue Reading
C&EN's August 18 Business Watch highlights two defining 2026 industry themes: BASF's historic Ludwigshafen workforce contraction and Khartis Therapeutics' launch, offering a snapshot of chemical restructuring and pharmaceutical innovation.
Eli Lilly's retatrutide enforcement campaign highlights why pharmaceutical manufacturers and regulatory agencies increasingly need coordinated strategies to address illicit compound markets. Faster market development is creating new challenges around monitoring, traceability and enforcement.
Eli Lilly's 2026 retatrutide crackdown offers a new benchmark for measuring the rapidly expanding illicit weight-loss drug market against prior-year GLP-1 enforcement and seizure data.
